Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07010692 · ClinicalTrials.gov registry record · Phase 1
Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment
A Phase 1 study of Squamous Cell Carcinoma and Skin Cancer, sponsored by Bruce Robinson, MD.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT07010692 is a Phase 1 study of Squamous Cell Carcinoma and Skin Cancer that is actively recruiting participants, run by Bruce Robinson, MD. The registered enrollment target is 100 participants, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target. The trial reports 1 study location across 1 state.
The verdict
NCT07010692, a Phase 1 study of Squamous Cell Carcinoma and Skin Cancer, is actively recruiting participants, sponsored by Bruce Robinson, MD.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, depending on the level of invasiveness, subjects may be instructed to apply the ointment over the course of five nights immediately following the treatment. The intention of this study is to minimize the need for invasive surgical procedures so as to optimize the cosmetic appearance, and provide a treatment option that is beneficial for a wide range of individuals.
Conditions Studied
Interventions
- DRUG Tirbanibulin ointment 1%
- DEVICE non-ablative fractional laser
Study Locations (1)
New York
- Bruce Robinson, MD - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2025-05-16 |
| Est. Completion | 2030-06 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07010692
The ClinicalTrials.gov registry entry for NCT07010692 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect, roughly in line with the 102-participant average among 47 other Squamous Cell Carcinoma trials with a reported enrollment target. The listed sponsor is Bruce Robinson, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Squamous Cell Carcinoma appearing as the primary indexed condition, and to 2 interventions - of which Tirbanibulin ointment 1% is the first listed.
NCT07010692 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.
Frequently Asked Questions
What is clinical trial NCT07010692 about?
NCT07010692 is a clinical study titled "Treating Basal and Squamous Cell Carcinomas With Fractional Laser and Tirbanibulin Ointment". The investigators seek to evaluate the effectiveness of fractional laser therapy and tirbanibulin ointment to treat squamous and basal cell carcinomas. This will be executed by using both thulium and erbium lasers on previously biopsy-confirmed SCCs and BCCs and applying bulk heating methods. Then, ...
What is the current status of trial NCT07010692?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 100 participants. The study started on 2025-05-16. Estimated completion is 2030-06.
What conditions does trial NCT07010692 study?
This clinical trial studies the following conditions: Squamous Cell Carcinoma, Skin Cancer, Keratinocyte Carcinoma, Basal Cell Carcinomas.
What interventions are being tested in trial NCT07010692?
The interventions under investigation include: Tirbanibulin ointment 1% (DRUG), non-ablative fractional laser (DEVICE).
Who is sponsoring clinical trial NCT07010692?
This trial is sponsored by Bruce Robinson, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07010692 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Squamous Cell Carcinoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors
RECRUITING · Phase 1
-
Intratumoral Lidocaine Injection Before Oropharyngeal Cancer Surgery
RECRUITING · Phase 1
-
Neo-adjuvant Treatment for Squamous Cell Carcinoma Using Direct Tumor Injection With RP1.
ACTIVE NOT RECRUITING · Phase 1
-
A Study of DKN-01 in Combination With Paclitaxel or Pembrolizumab
COMPLETED · Phase 1
-
A Pilot Study of Paclitaxel With Radiation Therapy for Locally Advanced Head and Neck Cancer
COMPLETED · Phase 1
-
Pembrolizumab in Combination With CRT for LA-SCCHN
COMPLETED · Phase 1
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.